Recently, other potential biomarkers have been investigated, such as tumor mutation burden (TMB), immune-score, cluster of differentiation 8 (CD8)-positive tumor-infiltrating lymphocytes and immune gene signature, but, to date, none have gained a definite role in clinical practice [12]. This evidence concerns the gene CD8A and neoplasm.